Andrea L Harzstark

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma
    Andrea L Harzstark
    Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143 1711, USA
    Cancer 117:4194-200. 2011
  2. ncbi Therapies in development for castrate-resistant prostate cancer
    Andrea L Harzstark
    Department of Medicine, University of California, San Francisco, 1600 Divisadero Street, Box 1711, San Francisco, CA 94115, USA
    Expert Rev Anticancer Ther 8:259-68. 2008
  3. ncbi Immunotherapeutics in development for prostate cancer
    Andrea L Harzstark
    Department of Medicine, University of California San Francisco, San Francisco, CA 94115, USA
    Oncologist 14:391-8. 2009
  4. ncbi Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study
    Terence W Friedlander
    Urologic Oncology Program, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
    Urol Oncol 30:408-14. 2012
  5. ncbi A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer
    Terence W Friedlander
    Genitourinary Medical Oncology Program, Biostatistics and Computational Biology Core, Helen Diller Family Comprehensive Cancer Center, Department of Bioengineering and Therapeutic Sciences, Box 1711, 1600 Divisadaro Street, University of California, San Francisco, San Francisco, CA 94115 1711, USA
    Oncol Rep 27:3-9. 2012
  6. ncbi Castrate-resistant prostate cancer: therapeutic strategies
    Andrea L Harzstark
    University of California, Urologic Oncology, San Francisco, CA 94143
    Expert Opin Pharmacother 11:937-45. 2010
  7. ncbi Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium
    Jonathan E Rosenberg
    Department of Medicine, University of California San Franscisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, Box 1711, San Francisco, CA 94115, USA
    J Clin Oncol 27:2772-8. 2009
  8. ncbi Sipuleucel-T for the treatment of prostate cancer
    Andrea L Harzstark
    Department of Medicine, University of California, San Francisco, California, USA
    Drugs Today (Barc) 44:271-8. 2008
  9. ncbi Novel therapeutic strategies in development for prostate cancer
    Andrea L Harzstark
    University of California, Department of Medicine, Box 1711, San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
    Expert Opin Investig Drugs 17:13-22. 2008
  10. ncbi Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge)
    Andrea L Harzstark
    University of California, Department of Medicine, Urologic Oncology 231, San Francisco, CA 94115, USA
    Expert Opin Biol Ther 7:1275-80. 2007

Detail Information

Publications10

  1. ncbi A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma
    Andrea L Harzstark
    Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143 1711, USA
    Cancer 117:4194-200. 2011
    ....
  2. ncbi Therapies in development for castrate-resistant prostate cancer
    Andrea L Harzstark
    Department of Medicine, University of California, San Francisco, 1600 Divisadero Street, Box 1711, San Francisco, CA 94115, USA
    Expert Rev Anticancer Ther 8:259-68. 2008
    ..This review will highlight the promise of these new approaches and the challenges to their development...
  3. ncbi Immunotherapeutics in development for prostate cancer
    Andrea L Harzstark
    Department of Medicine, University of California San Francisco, San Francisco, CA 94115, USA
    Oncologist 14:391-8. 2009
    ....
  4. ncbi Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study
    Terence W Friedlander
    Urologic Oncology Program, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
    Urol Oncol 30:408-14. 2012
    ..In this study, the efficacy of depot octreotide acetate was prospectively evaluated in patients with CRPC...
  5. ncbi A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer
    Terence W Friedlander
    Genitourinary Medical Oncology Program, Biostatistics and Computational Biology Core, Helen Diller Family Comprehensive Cancer Center, Department of Bioengineering and Therapeutic Sciences, Box 1711, 1600 Divisadaro Street, University of California, San Francisco, San Francisco, CA 94115 1711, USA
    Oncol Rep 27:3-9. 2012
    ..NDGA therapy lengthens median PSADT but does not induce significant PSA declines. Further study may require a placebo-control to determine if changes in PSADT are drug related...
  6. ncbi Castrate-resistant prostate cancer: therapeutic strategies
    Andrea L Harzstark
    University of California, Urologic Oncology, San Francisco, CA 94143
    Expert Opin Pharmacother 11:937-45. 2010
    ..Castrate-resistant prostate cancer continues to be inadequately addressed by currently available therapies...
  7. ncbi Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium
    Jonathan E Rosenberg
    Department of Medicine, University of California San Franscisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, Box 1711, San Francisco, CA 94115, USA
    J Clin Oncol 27:2772-8. 2009
    ..Mitoxantrone plus prednisone and ixabepilone each have modest activity as second-line chemotherapy in docetaxel-refractory castration-resistant prostate cancer (CRPC) patients. Clinical noncrossresistance was previously observed...
  8. ncbi Sipuleucel-T for the treatment of prostate cancer
    Andrea L Harzstark
    Department of Medicine, University of California, San Francisco, California, USA
    Drugs Today (Barc) 44:271-8. 2008
    ..This review summarizes the clinical trials evaluating sipuleucel-T and discusses its potential role in the treatment of prostate cancer...
  9. ncbi Novel therapeutic strategies in development for prostate cancer
    Andrea L Harzstark
    University of California, Department of Medicine, Box 1711, San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
    Expert Opin Investig Drugs 17:13-22. 2008
    ..This review will highlight recent and current studies for many of the promising developments for advanced disease, as well as novel early stage approaches...
  10. ncbi Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge)
    Andrea L Harzstark
    University of California, Department of Medicine, Urologic Oncology 231, San Francisco, CA 94115, USA
    Expert Opin Biol Ther 7:1275-80. 2007
    ..This review summarizes the clinical trials using APC8015 in prostate cancer and discusses its future role in the treatment of prostate cancer...